FinalDose
ActiveProgrammable DNA drug destroying all cancers, unlocking 80% of targets
About
FinalDose is building the first programmable drug - a single smart drug molecule that you can insert any diseased genetic code and it can search and destroy cells upon DNA recognition. Unlocking 80% of undruggable targets today. Starting with all cancers.
Founders · 3
Founder at FinalDose (YC P26). DPhil in Biochemistry from Oxford, where he spent 5 years as a postdoctoral researcher at the MRC Weatherall Institute of Molecular Medicine. Led CRISPR screening projects uncovering new druggable targets in cancer cells and built pipelines reducing hit validation time from months to 7 days. Research focuses on BRCA1-deficient cancers and PARP inhibitor resistance mechanisms.
Cofounder and CTO at FinalDose (YC P26). Oxford PhD in Computational Biology with Wellcome Trust full scholarship. Previously Data Lead at Gutsee Biotech. Developed novel machine learning method to use coevolution biology to identify genetic targets that convey drug resistance in viruses. During SARS-CoV-2 pandemic, led UK biobank analysis of human genetics susceptibility for infections
CEO @ FinalDose (YC P26). Oxford PhD in Oncology. Previous startup (Vivid Dx) solved a multi-decade bottleneck in sepsis diagnostics: low biomass isolation. By overcoming this hurdle, we built the world’s fastest diagnostic system - slashing wait times from 5 days to just 30 minutes. Raised $15M in venture backing.
Launch
FinalDose is building the first programmable drug platform - a single smart drug molecule that finds diseased cells by their DNA and destroys them. We’re starting with all cancers.
FinalDose builds a programmable drug platform that uses a DNA-sensing molecule to identify diseased cells by their DNA and trigger cell death, starting with cancers driven by DNA sequences. The platform aims to reprogram the same molecule with different DNA targets to treat diseases identifiable at the DNA level, reducing development time and cost.
Related startups
AI and Data for Cancer Therapeutics
The agentic drug company. We simulate human biology.
